CAPOX Regimen Appears Noninferior to FOLFOX in Colorectal …
Oct 8, 2023 · The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and …
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), …
FDA Grants Taletrectinib Priority Review in ROS1+ Advanced NSCLC
Dec 23, 2024 · The FDA has granted priority review to the new drug application (NDA) for taletrectinib, a treatment for patients with ROS1-positive advanced non–small cell lung cancer …
Evaluating the Impact of Neoadjuvant Therapy in Localized Breast …
Dec 24, 2024 · NAC and Lymph Node Disease. The benefits of using NAC to eradicate nodal disease have been documented by a number of investigators. 10 Mamtani A et al 10 showed …
FDA Approves Subcutaneous Nivolumab Across Existing Solid …
Dec 27, 2024 · The FDA has approved the subcutaneous formulation of nivolumab (Opdivo). This approval makes it the first and only subcutaneously administered PD-1 inhibitor. …
GLP-1 Agonists Poised to Impact Breast Cancer Care
Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing …
The Impact of T-DXd in HER2-Positive Breast Cancer
Oct 23, 2024 · Tanya Gupta, MD, medical oncologist in the Stanford University Department of Medicine, Division of Medical Oncology, evaluates fam-trastuzumab deruxtecan-nxki (Enhertu; …
IMforte Shows Benefits of Lurbinectedin/Atezolizumab in ES-SCLC
Oct 15, 2024 · Lurbinectedin (Zepzelca) plus the PD-L1 inhibitor atezolizumab (Tecentriq) led to positive topline results in the phase 3 IMforte study (NCT05091567) vs atezolizumab alone …
Dual Immunotherapy Clinically Active in Anaplastic Thyroid Cancer
Dec 23, 2024 · Dual immune checkpoint inhibition with nivolumab (Opdivo) and ipilimumab (Yervoy) shows promise for the treatment of anaplastic thyroid cancer (ATC), but offers limited …
Real-World Data Enhance Optimal Use of Cellular Therapies
Dec 24, 2024 · Therapeutic opportunities for hematologic malignancies have rapidly advanced over the past 8 years. In particular, the advent of cellular therapies, such as chimeric antigen …